20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates
Globe Newswire•16/11/2026•16:05 ET
0
Key Highlights
- ➤OneTest revenue rose 4.1% to $1.36 million through nine months
- ➤OneTest gross margin expanded to 32.8% from 29.5%
- ➤Vermont signed two-year contract covering approximately 4,500 firefighters
- ➤Cash reached $3.63 million with no outstanding borrowings
- ➤Nine-month net loss widened to $5.06 million from $2.43 million
Expert Statements
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs
“OneTest™ revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%. While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont’s program shifted into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before year-end.”
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs
“We are also working on new ways to reach more customers. Our franchise model would allow established regional laboratories to offer OneTest™ in their markets, without requiring us to build a national sales force. We have received preliminary interest from laboratories in the United States and plan to begin licensing our protein tumor marker approach to clinical laboratories in 2027.”
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs
“With more than 25,000 firefighters screened to date, we are continuing to build the real-world evidence to support our regulatory strategy. We believe recent developments in the MCED testing industry are encouraging, and we remain focused on our goal of obtaining FDA authorization and Medicare reimbursement for OneTest™ for Cancer by the end of 2028”
Alan Bergman, Chief Financial Officer of 20/20 BioLabs
“We ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025. Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially.”
Alan Bergman, Chief Financial Officer of 20/20 BioLabs
“Gross margin was lower this quarter due to reduced testing volume, but our laboratory has the capacity to support additional testing without a corresponding increase in certain operating costs. As testing under the Vermont contract and other programs increases, we expect to benefit from better utilization of our existing laboratory capacity while continuing to manage expenses.”
OneTest™ Revenue Increased 4.1% to $1.36 Million for First Nine Months of 2026, with Gross Margin Expanding to 32.8%
Vermont Executes Two-Year Firefighter Cancer Screening Contract with Testing Expected to Contribute Revenue in Q4
Get started
Create a free account to read the full story.
